Immunogenic cell stress and injury versus immunogenic cell death: implications for improving cancer treatment with immune checkpoint blockade

Thumbnail Image
Download
Name

Immunogenic cell stress and injury versus immunogenic cell death implications for improving cancer treatment with immune checkpoint blockade.pdf

Description
Published version
Size

1.07 MB

Format

Adobe PDF

Checksum (MD5)

5007fa46d2884efbb5ade10a3fae7e13

sword-2023-01-09T18:32:52.original.xml (130 B)
Original SWORD entry document
Author(s)
Sriram, Ganapathy
•
Emmons, Tiffany R
•
Milling, Lauren E
•
Irvine, Darrell J
•
Yaffe, Michael B
Date Issued
2022
Journal
Molecular & Cellular Oncology
Publisher
Informa UK Limited
Citation
Sriram, Ganapathy, Emmons, Tiffany R, Milling, Lauren E, Irvine, Darrell J and Yaffe, Michael B. 2022. "Immunogenic cell stress and injury versus immunogenic cell death: implications for improving cancer treatment with immune checkpoint blockade." Molecular & Cellular Oncology, 9 (1).
Version
Final published version
Abstract
Inducing immunogenic tumor cell death to stimulate the response to immune checkpoint blockade has not yet been effectively translated into clinical practice. We recently discovered that stressed/injured but still viable tumor cells are critical for T-cell priming and substantially improve responses to systemic anti-PD1/CTLA4. Therapeutic tumor cell injury, rather than complete killing, in the tumor microenvironment may enhance efficacy of immunotherapy in various cancers.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Terms of Use
Creative Commons Attribution 4.0 International license
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1080/23723556.2022.2039038
PrivacyPermissionsAccessibilityContact us
Notify us about copyright concerns.